Background. Previously we conducted a double-blind controlled, randomized efficacy field trial of gD-2 HSV vaccine adjuvanted with ASO4 in 8323 women. Subjects had been previously selected to be seronegative for HSV-1 and HSV-2. We found that vaccine was 82% protective against HSV-1 genital disease, but offered no significant protection against HSV-2 genital disease.
Previously we conducted a pivotal, double blind, hepatitis A (HAV) vaccine controlled, randomized efficacy field trial of an investigational vaccine consisting of herpes simplex virus type 2 (HSV-2) glycoprotein D (gD-2) adjuvanted with AS04 (gD-2/AS04) in 8323 women who were doubly seronegative for HSV-1 and HSV-2 [1] . The results were surprising. First, the majority of cases of genital disease (60% in the control HAV vaccine group) were caused by HSV-1, not HSV-2 [1, 2] . Second, while no protection against HSV-2 was demonstrated, the vaccine was efficacious at preventing HSV-1 disease and infection (82% protection against culture confirmed genital disease). To our knowledge no immune/immunologic correlate of protection has been established for any HSV induced disease in humans or animals. This study provided us the opportunity to examine humoral and cellular immune responses in breakthrough infected subjects to evaluate these parameters as possible correlates of protection against infection with HSV-1 or HSV-2.
MATERIALS AND METHODS

Ethics Statement
The study was performed under an investigational new drug application reviewed by the US Food and Drug Administration and received approval from the Saint Louis University Institutional Review Board (IRB) as well as the IRBs of the 49 other participating institutions. Written informed consent was obtained from each volunteer in accordance with the Code of Federal Regulations (21 CRF 50) and International conference on Harmonisation guidelines for Good Clinical Practice (ICH E6). The National Institute of Allergy and Infectious Diseases (NIAID) Data Safety Monitoring Board reviewed all safety data at regular intervals during the study.
Study Design
The design and results of the clinical trial have been published [1, 2] . Briefly, in the double-blind, randomized controlled trial (RCT), women were screened by HSV-1 and -2 Western Blot, and doubly seronegative women were randomized to receive either three doses of gD-2/AS04 HSV vaccine or HAV vaccine. Subjects were vaccinated at times 0, 1 and 6 months. Serum was collected at time 0 (prior to dose 1), month 2 (one month post dose 2), month 6 (prior to dose 3), month 7 (one month post dose 3), and months 12, 16 and 20. Peripheral blood mononuclear cells (PBMCs) were collected from approximately half of the subjects for cryopreservation at month 2 (one month post dose 2) and month 7 (one month post dose 3).Within the parent RCT, nested case-cohort and case-control studies were used to identify possible immunological correlates of protection against infection and genital herpes disease caused by HSV-1 or HSV-2.
Case-Control Studies of ELISA and CMI Nested case-control studies were selected as an efficient method to assess the correlation between ELISA or CMI response and incidence of HSV infection. All subjects with HSV infection (with or without disease) were included as cases regardless of protocol adherence, timing of infection, or presence of symptomatic disease. CMI testing was performed while the RCT was ongoing, whereas the ELISA testing was performed after the completion of the RCT. Therefore, the CMI analysis includes only those cases identified prior to 2008, whereas the ELISA analysis includes all cases. Both HSV and HAV vaccine recipients were sampled in each study. The results presented in this manuscript are based on re-analysis of the data that applies a retrospective and final determination of eligibility for the analysis populations and determination of HSV infection and/ or disease status, and focuses on the HSV vaccine group as relevant to the identification of a correlate of protection.
The case-control correlates of protection analysis considers ELISA or CMI responses at several time points, including 1) the "index visit", the study visit closest to the date of infection for the index case, and 2) month 7, one month after the receipt of the third and final dose of study product, when peak response is expected. For the analysis of the immune response at the "index" visit closest to infection, three controls were individually matched to each index case as described below, and their response data was selected from the index visit specific to that the index case.
For the CMI case-control study, uninfected controls were originally selected for testing using the nearest available pair matching method, with distance calculated by propensity scores [3] . However, due to poor cell viability approximately 25% of subjects did not have any CMI results available, and 50% of subjects only had results available for only one time point, so even though six controls had been selected for each case, after testing was complete there were several cases without any matched controls, or without a matched control for their "index" visit result. Therefore, prior to analysis the total pool of controls was re-matched to cases using a simpler strategy that matched on the demographic factors considered in randomly allocating vaccine product in the parent RCT. For the CMI study, post-hoc matching resulted in up to three controls for each case, with exact matches for 97% of cases on age (18-22, 23-26, 27-30), 97% of cases on race (White, non-White), and 94% on both factors. With the benefit of hindsight, controls for the ELISA study were selected from the onset using the strategy of exact matching on age and race, and all cases have up to 3 controls matched exactly on these factors.
Case-Cohort Study of ELISA A prospective case-cohort design was performed to permit the assessment of incidence rates as well as odds ratios for events of interest. The case-cohort study is also cost-effective because samples are obtained prospectively on all subjects but are only tested in a subset of participants. In the RCT, sera samples were collected for all women, but were tested for ELISA responses in all women with HSV infection, and a random subset of 5% of HAV recipients, and 20% of HSV recipients. Specifically, the case-cohort study included all HSV-infected cases regardless of protocol adherence, timing of infection, or presence of symptomatic disease. To be eligible for the study, subjects must have been enrolled in the RCT, have received all 3 doses of HSV vaccine, been infection-and disease-free prior to month 7, and have met other requirements for the according-to-protocol (ATP) month 7-20 subset in the RCT analysis [1] .
Laboratory Methods
gD-2 ELISA Assay
The quantitative analysis of antibodies to gD-2 antigen in human serum was carried out by direct ELISA. Briefly, purified gD-2 (GSK in-house production, 5 µg/mL in Dulbecco's Phosphate Buffered Saline (DPBS) was coated (o/n, 4°C) onto 96-well microtitration plates (Nunc-Immunoplate Maxisorp 96-wells). After washing (NaCl 150 mM -Tween 0.05%), nonspecific binding sites were blocked with a DPBS solution (PO 4 0.0095M -pH 7.4) containing 1% Bovine serum albumin (BSA) (Sigma A-2153-50G) for 1 hour at 37°C. Excess of saturation solution is washed (NaCl 150 mM-Tween 0.05%). Next, successive 2-fold dilutions of sera, control sera and standards were added and incubated for 1 hour at RT. After washing, biotinylated-secondary antibody (sheep anti-human immunoglobulin -Amersham RPN1003) was added for 1 hour at 37°C. A biotinylated peroxidase-streptavidin complex (Pierce 21 126) was applied (30 minutes, 37°C) to amplify the reaction, and bound HRP was detected using OPDA (OrthoPhenyleneDiAmine -Sigma P8412). The resulting orange color was quantitated spectrophotometrically (490 nm-620 nm; Molecular Device Emax). The color intensity was proportional to the antigD antibodies concentration in the serum sample. ELISA titers were calculated from a reference standard curve using a four parameters fitting algorithm and expressed in arbitrary ELISA units (EU/mL). ELISA testing was performed in two batches; for any subjects with duplicate results, the ELISA titer from the later batch was used for analysis.
Western Blot Analysis
Western blot (WB) analysis (University of Washington Clinical Virology Laboratory at Seattle Children's Hospital) was used to confirm HSV-1-or HSV-2-seronegative status at study entry and seroconversion during the follow-up period [4] . Seroconversion to HSV-1 or HSV-2 was defined as a positive Western blot analysis in a subject with a previously negative analysis for the corresponding HSV type.
Cell Mediated Immune (CMI) Response Assay
An adaptation of the intracellular cytokine staining (ICS) method of Maeker, et al, was used [5] . Cryopreserved PBMCs were thawed, washed, examined for viability, counted (Sysmex) and resuspended to 2 × 10 7 cells/mL in culture medium. They were then stimulated in vitro using a pool of overlapping 15-mer peptides (1.25 µg/mL for each peptide), which covered the sequence of the gD-2 antigen. Brefeldin A was added to inhibit cytokine secretion. The cells were incubated with anti-CD4-PerCP and anti-CD8-APC-H7, fixed and permeabilized. Expression of specific immune markers was assessed by incubation with anti-IFN-γ-FITC, anti-IL-2-APC, anti-TNF-α-PE-Cy7, and anti-CD40L-PE followed by flow cytometric analysis. Results were expressed as frequencies of CD4 + or CD8 + T cells expressing two or more immune markers (among CD40L, IFN-γ, IL-2, and TNF-α) per million total CD4 + or CD8 + T cells as previously described [6] .
Samples were analysed only if cell viability was 70% or greater.
Statistical Analysis
Case-Control Study of ELISA and CMI The ELISA response was analyzed using separate conditional logistic regression models fit for each HSV infection and/or disease status (HSV-1 infection, HSV-1 disease, HSV-1 culture confirmed disease, HSV-2 infection, HSV-2 disease, HSV-2 culture confirmed disease) against log-transformed gD-2 ELISA titers among subjects who received the investigational HSV vaccine. Models using the titer from the "index" visit were fit for Month 2 Subset, defined as subjects who received at least 2 doses of HSV vaccine, were infection-and disease-free prior to month 2, and met other requirements for the ATP month 2-20 Figure 1 . A and B, Subjects in the Case-Cohort study were classified into seven groups based on ELISA titers at month 7. The sample size of each group is displayed below the x-axis. The observed probability of HSV infection was calculated within each group and is plotted along with a 95% confidence interval band. The probability of infection was estimated using the weighted log-poisson regression model (Table 1) , and is plotted as a dashed line. The proportion (and 95% CI) of subjects in the HAV arm of the RCT with infection is displayed as reference. subset in the main study analysis [1] . In these analyses the logistic regression model conditioned on the index case number. Matching at the level of the individual case was required because of the need to select the titer from the matched controls at the index visit, which differs from case to case.
Models using the titer from the month 7 visit were fit for the Month 7 subset, defined as subjects who received all 3 doses of HSV vaccine, were infection-and disease-free prior to month 7, and met other requirements for the ATP month 7-20 subset in the main study analysis [1] . The month 7 titer data was analyzed analogously to the index visit titer data, by fitting a logistic regression model that conditioned on the index case number. However, it was noted that matching at the level of the individual case was not required because the month 7 visit, unlike the index visit, does not vary between cases.
Therefore, the month 7 titer data was re-analyzed using m:n matching in which each of the "m" cases and "n" controls that shared the same demographic factors were pooled into a demographic stratum. The logistic regression model was then fit conditioning on these demographic strata. The use of a stratified m:n matching instead of an individual 3:1 matching permitted the inclusion of data from both the case control and case cohort subsets in the re-analysis, and improved the statistical power available to detect any vaccine effect.
Similarly, the CMI response was analyzed using separate conditional logistic regression models fit for each infection endpoint (HSV-1, HSV-2) against each of the immunologic correlates (CD40L, INF-γ, IL-2, TNF-α, and response to at least 2 cytokines tested in CD4 and in CD8 cells) collected at each time point (Month 7, and the "index" visit) within each treatment group.
Case-Cohort Study of ELISA Separate weighted log-poisson regression models were fit for each HSV-status against month 7 ELISA titers among HSV vaccinees in the Month 7 subset; uninfected subjects represented a 20% random sample of eligible subjects, and were thus given a weight of 5 in the model. Using the parameter estimates from the weighted logistic regression model, the HSV-1 infection rate in the vaccine arm was estimated over the range of month 7 ELISA titers. Finally, subjects in the Case-Cohort study were classified into groups based on ELISA titers at month 7. For each group the vaccine efficacy (VE) was estimated as one minus the Figure 2 . Vaccine efficacy (VE) displayed as a function of post vaccine antibody titer. The observed VE to prevent HSV-1 infection (with or without disease) was calculated within each group and is plotted along with a 95% confidence interval band. VE was also estimated from the weighted log-bin model from case-cohort study (Table 1) , and is plotted as a solid line. The shaded area represents the 95% bootstrap CI.
ratio of the estimated HSV-1 infection rate in the group to the observed infection rate in the HAV arm of the RCT. Confidence bounds for VE were estimated using the bootstrap method.
RESULTS
HSV gD-2 ELISA antibody concentrations correlated with protection from HSV-1, but not HSV-2, infection ( Figure 1 ). The percent of subjects infected from among subjects with the lowest post-vaccine antibody concentrations (antibody titer <10 3 ) was 2.5% for HSV-1 and fell to <1% for the subjects with the highest antibody responses to vaccine (mean titer >10 4 ). In contrast, antibody to HSV-2 did not significantly correlate with infection rates over the range of antibody responses.
Comparison of results from the Case-Control and CaseCohort studies examining gD-2 binding antibody concentration as a correlate for protection against HSV-1 infection is shown in Table 1 . No correlation was found between HSV gD-2 ELISA titers and HSV-2 infection or disease (data not shown). Statistically significant correlations between antibody concentration and HSV-1 endpoints were found (in all models, with higher antibody concentrations being associated with lower rates of HSV-1 infection or disease). Vaccine efficacy against HSV-1 infection (with or without disease) was calculated over the range of observed antibody titers (Figure 2) , and higher antibody titers were associated with higher vaccine efficacy. In contrast to the correlation between humoral immune response to gD-2 antigen and vaccine efficacy, cell mediated immunity to gD-2 antigen did not correlate with protection against either HSV-1 or HSV-2. CD4 T cell responses (Tables 2  and 3) , as assessed by an ICS assay, among the HSV vaccine and HAV vaccine control subsets who acquired HSV-1 or HSV-2 infection after month 7, were compared to those who were never infected and are shown in box plots for CD40L ( Figure 3A) , INF-γ ( Figure 3B ), IL-2 ( Figure 3C ) and TNF-α ( Figure 3D ). As expected, there were differences in CD4 T cell responses to gD-2 antigen between the HSV and HAV vaccine groups (Tables 2 and 3 ) with responses present in HSV vaccinees but not in HAV vaccine controls. In no instance was there a significant difference in CD4 T cell response between infected and uninfected HSV vaccine recipients. Also the comparison of subjects with at least 2 cytokines positive showed no difference between infected and uninfected HSV vaccinees, as previously reported.
1 CD8 T cell responses to the HSV vaccine at the time points sampled were largely negative (data not shown). Antibody responses were significantly correlated with CD4 responses, r = 0.471 (Figure 4 ). Although this correlation was statistically significant, as noted above, vaccine efficacy was associated only with antibody responses and not CMI responses.
This may mean that the relationship between antibody response and CMI response is relatively weak.
We took this opportunity to evaluate the CMI responses to gD-2 among HAV vaccinees who developed natural infection with HSV-1 or HSV-2 in order to assess the magnitude of CD4 and CD8 responses to gD-2 after infection (Table 3) . HAV vaccinees never infected with HSV-1 or 2 had very low frequency (range 5-14 cells per 10 6 ) of cells exhibiting ICS with any of the measured cytokines (Table 3) . HSV infected HAV vaccinees exhibited activated cell frequencies up to 150/per 10 6 cells depending on the cytokine. Infection plus gD-2 vaccine gave the highest responses. HSV infected gD-2 vaccinees had high TNFα for example) ( Table 3) .
In order to have a basis for understanding the post vaccine gD antibody titers relative to antibody induced by natural infection, we evaluated the antibody response to HSV-1 or HSV-2 infection among the subjects who received HAV (control) vaccine and became infected. We evaluated sera from all time points ( pre-vaccine, and months 2, 6, 7, 12, 16 and 20). We estimated the infection time from either laboratory confirmed disease or seroconversion by commercially available serodiagnostic testing as previously described [1] . Post infection ELISA antibody titer to gD was taken as the highest titer after the estimated infection date. We also compared post infection gD titers among the groups with infection (with or without disease) vs the groups with disease (Table 4) . HSV-1 or HSV-2 infection resulted in lower gD antibody than vaccine. This was true whether we examined the group with infection (with or without disease) or those with HSV-1 or HSV-2 disease. The groups with disease had significantly more post infection antibody than the overall groups (with or without disease), but the vaccinees developed higher post vaccine antibody titers compared to titers after natural infection in HAV control subjects.
DISCUSSION
The results of the present laboratory study provide partial explanations to finding protection against HSV-1 disease and infection after administration of an adjuvanted HSV gD-2 vaccine. ELISA binding antibody to gD-2 correlated with protection against HSV-1. This most likely reflects the high degree of homology between the form of gD-2 used in the investigational vaccine and the corresponding region of gD-1 (84% amino acid homology, GSK unpublished data) and also reflects that antibodies to gD-2 have neutralizing activity. Additional laboratory studies are needed to more completely understand the gD epitopes associated with HSV-1 neutralization and to understand the failure of vaccine to protect against HSV-2 or the lack of correlation of gD-2 antibody with protection from HSV-2 infection or disease. The antibody titers required for HSV-2 protection may be higher than those needed to protect against HSV-1.
Previously we noted that protection against oral HSV-1 disease was not demonstrated, but significant protection against culture positive HSV-1 genital disease (82% protection) was afforded by the gD-2/AS04 vaccine. This most likely is due to vaccine inducing serum IgG (the major immunoglobulin of the genital tract) and presumably not secretory IgA (the major component of immunoglobulin of the mouth and upper respiratory tract). The resulting protection would therefore be manifest in the genital tract but not in the mouth. Some support for this hypothesis is found in the literature. In a study of a different subunit vaccine containing gB and gD, IgG and IgA was induced in cervical secretions post-vaccine in vaccinated women; however, IgG titers were >10 fold higher than IgA titers [7] .
The results of our clinical trial were surprising in that vaccine, despite containing HSV-2 gD, was not protective against HSV-2. This is in contrast to two previous smaller tests of concept trials conducted in discordant couples in which one subject had recurrent HSV-2 disease and the partner was uninfected [8] . In both of these studies doubly seronegative women (but not men) were protected from disease after gD-2/AS04 vaccination (about 70% protection in both studies). The significant difference in results of the field trial which was conducted in women more representative of the HSV seronegative general population vs uninfected women who were partners of infected persons probably resides in the selection bias for uninfected women of infected partners. Perhaps this latter group is more resistant to HSV infection and adding vaccine induced antibodies to partial natural resistance translated into vaccine efficacy. Could CMI be this natural resistance factor? As noted by the present report the investigational HSV vaccine did induce CD4 cells that produced cytokines on exposure to the vaccine Figure 4 . Displays the correlation between ELISA and CD4 cells with response to at least 2 cytokines. Although a weak correlation of antibody response and CD4 All was found, higher CD4 responses did not correlate with protection from infection. antigen. CD8 cells were not induced by vaccine. There was no correlation of the presence of vaccine induced CD4 CMI with protection against infection, although peripheral blood CD4 responses may not adequately represent what is happening in the mucosa. Nevertheless, exposed but antibody negative women in discordant couples might have CMI that provide some level of modest protection. Clearly there is not complete protection in apparently uninfected women in discordant couples since the attack rate was high (10%) in the placebo subjects in those two earlier discordant couple studies [8] . The significant protection against HSV-1 in our study was associated with antibody to vaccine and suggests that strategies to prevent HSV-1 and HSV-2 infection could focus on inducing higher levels of antibody. An efficacy trial of HSV-2 vaccine consisting of gB + gD antigens with MF59 adjunct also failed to show efficacy against HSV-2 despite the induction of neutralizing antibody for HSV-2 [9] . Comparisons with the present study are confounded by study design differences. In the earlier study the populations studied were considered high risk (discordant couples and STD clinic attendees) for HSV-2 infection and the majority were male (69%) and HSV-1 antibody positive (62%) (9) . HSV-1 infection attack rates were not reported in the study of gB + gD vaccine [9] . Subsequent laboratory studies found that ADCC antibody responses were relatively low to the gB + gD vaccine, and the investigators suggested that ADCC may need to be a component of the antibody responses to confer protection against HSV-2 [10] .
The antibody titers to gD-2 induced by vaccine in the present study were approximately 2-6 fold higher than observed after primary HSV-1 or HSV-2 infection. Vaccine induced approximately 6 fold higher antibody than observed in infected control subjects (with or without disease) and was 2 fold higher in vaccinees than antibody observed in controls after naturally occurring primary HSV-1 or HSV-2 disease. Additional laboratory studies to characterize the responses observed in the present report are ongoing. Further clinical studies with vaccines containing gD-2 that induce even higher levels of antibody to HSV-2 with neutralizing activity and perhaps also ADCC activity could facilitate the further understanding of the level of antibody and functionality of the antibody needed to confer protection against both HSV-1 and HSV-2.
